Loading...
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
BACKGROUND: Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. METHODS: In this multicenter, prospective, observational study of adults treated with MEC whi...
Na minha lista:
| Udgivet i: | BMC Pharmacol Toxicol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7539512/ https://ncbi.nlm.nih.gov/pubmed/33023657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-020-00445-y |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|